BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 31578311)

  • 21. Patient-specific naturally gene-reverted induced pluripotent stem cells in recessive dystrophic epidermolysis bullosa.
    Tolar J; McGrath JA; Xia L; Riddle MJ; Lees CJ; Eide C; Keene DR; Liu L; Osborn MJ; Lund TC; Blazar BR; Wagner JE
    J Invest Dermatol; 2014 May; 134(5):1246-1254. PubMed ID: 24317394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinically Relevant Correction of Recessive Dystrophic Epidermolysis Bullosa by Dual sgRNA CRISPR/Cas9-Mediated Gene Editing.
    Bonafont J; Mencía Á; García M; Torres R; Rodríguez S; Carretero M; Chacón-Solano E; Modamio-Høybjør S; Marinas L; León C; Escamez MJ; Hausser I; Del Río M; Murillas R; Larcher F
    Mol Ther; 2019 May; 27(5):986-998. PubMed ID: 30930113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa.
    Wagner JE; Ishida-Yamamoto A; McGrath JA; Hordinsky M; Keene DR; Woodley DT; Chen M; Riddle MJ; Osborn MJ; Lund T; Dolan M; Blazar BR; Tolar J
    N Engl J Med; 2010 Aug; 363(7):629-39. PubMed ID: 20818854
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa.
    Venugopal SS; Yan W; Frew JW; Cohn HI; Rhodes LM; Tran K; Melbourne W; Nelson JA; Sturm M; Fogarty J; Marinkovich MP; Igawa S; Ishida-Yamamoto A; Murrell DF
    J Am Acad Dermatol; 2013 Dec; 69(6):898-908.e7. PubMed ID: 24075228
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Construction of skin equivalents for gene therapy of recessive dystrophic epidermolysis bullosa.
    Gache Y; Baldeschi C; Del Rio M; Gagnoux-Palacios L; Larcher F; Lacour JP; Meneguzzi G
    Hum Gene Ther; 2004 Oct; 15(10):921-33. PubMed ID: 15585108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human COL7A1-corrected induced pluripotent stem cells for the treatment of recessive dystrophic epidermolysis bullosa.
    Sebastiano V; Zhen HH; Haddad B; Bashkirova E; Melo SP; Wang P; Leung TL; Siprashvili Z; Tichy A; Li J; Ameen M; Hawkins J; Lee S; Li L; Schwertschkow A; Bauer G; Lisowski L; Kay MA; Kim SK; Lane AT; Wernig M; Oro AE
    Sci Transl Med; 2014 Nov; 6(264):264ra163. PubMed ID: 25429056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Keratinocyte cell lines derived from severe generalized recessive epidermolysis bullosa patients carrying a highly recurrent COL7A1 homozygous mutation: models to assess cell and gene therapies in vitro and in vivo.
    Chamorro C; Almarza D; Duarte B; Llames SG; Murillas R; García M; Cigudosa JC; Espinosa-Hevia L; Escámez MJ; Mencía A; Meana A; García-Escudero R; Moro R; Conti CJ; Del Río M; Larcher F
    Exp Dermatol; 2013 Sep; 22(9):601-3. PubMed ID: 23947675
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetically corrected iPSCs as cell therapy for recessive dystrophic epidermolysis bullosa.
    Wenzel D; Bayerl J; Nyström A; Bruckner-Tuderman L; Meixner A; Penninger JM
    Sci Transl Med; 2014 Nov; 6(264):264ra165. PubMed ID: 25429058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene editing toward the use of autologous therapies in recessive dystrophic epidermolysis bullosa.
    Perdoni C; Osborn MJ; Tolar J
    Transl Res; 2016 Feb; 168():50-58. PubMed ID: 26073463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Deconstructing progressive inflammatory fibrosis in recessive dystrophic epidermolysis bullosa.
    Ebens CL
    EMBO Mol Med; 2021 Oct; 13(10):e14864. PubMed ID: 34515407
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term follow-up of patients with recessive dystrophic epidermolysis bullosa in the Netherlands: expansion of the mutation database and unusual phenotype-genotype correlations.
    van den Akker PC; van Essen AJ; Kraak MM; Meijer R; Nijenhuis M; Meijer G; Hofstra RM; Pas HH; Scheffer H; Jonkman MF
    J Dermatol Sci; 2009 Oct; 56(1):9-18. PubMed ID: 19665875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Collagen VII Expression Is Required in Both Keratinocytes and Fibroblasts for Anchoring Fibril Formation in Bilayer Engineered Skin Substitutes.
    Supp DM; Hahn JM; Combs KA; McFarland KL; Schwentker A; Boissy RE; Boyce ST; Powell HM; Lucky AW
    Cell Transplant; 2019; 28(9-10):1242-1256. PubMed ID: 31271052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review of collagen VII sequence variants found in Australasian patients with dystrophic epidermolysis bullosa reveals nine novel COL7A1 variants.
    Dang N; Klingberg S; Marr P; Murrell DF
    J Dermatol Sci; 2007 Jun; 46(3):169-78. PubMed ID: 17425959
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Replenishment of type VII collagen and re-epithelialization of chronically ulcerated skin after intradermal administration of allogeneic mesenchymal stromal cells in two patients with recessive dystrophic epidermolysis bullosa.
    Conget P; Rodriguez F; Kramer S; Allers C; Simon V; Palisson F; Gonzalez S; Yubero MJ
    Cytotherapy; 2010 May; 12(3):429-31. PubMed ID: 20230217
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Maintenance of chronicity signatures in fibroblasts isolated from recessive dystrophic epidermolysis bullosa chronic wound dressings under culture conditions.
    De Gregorio C; Catalán E; Garrido G; Morandé P; Bennett JC; Muñoz C; Cofré G; Huang YL; Cuadra B; Murgas P; Calvo M; Altermatt F; Yubero MJ; Palisson F; South AP; Ezquer M; Fuentes I
    Biol Res; 2023 May; 56(1):23. PubMed ID: 37161592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Footprint-free gene mutation correction in induced pluripotent stem cell (iPSC) derived from recessive dystrophic epidermolysis bullosa (RDEB) using the CRISPR/Cas9 and piggyBac transposon system.
    Itoh M; Kawagoe S; Tamai K; Nakagawa H; Asahina A; Okano HJ
    J Dermatol Sci; 2020 Jun; 98(3):163-172. PubMed ID: 32376152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. COL7A1 Editing via CRISPR/Cas9 in Recessive Dystrophic Epidermolysis Bullosa.
    Hainzl S; Peking P; Kocher T; Murauer EM; Larcher F; Del Rio M; Duarte B; Steiner M; Klausegger A; Bauer JW; Reichelt J; Koller U
    Mol Ther; 2017 Nov; 25(11):2573-2584. PubMed ID: 28800953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impaired Wound Healing, Fibrosis, and Cancer: The Paradigm of Recessive Dystrophic Epidermolysis Bullosa.
    Tartaglia G; Cao Q; Padron ZM; South AP
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ABCB5
    Dieter K; Niebergall-Roth E; Daniele C; Fluhr S; Frank NY; Ganss C; Kiritsi D; McGrath JA; Tolar J; Frank MH; Kluth MA
    Cytotherapy; 2023 Jul; 25(7):782-788. PubMed ID: 36868990
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transcriptomic profiling of recessive dystrophic epidermolysis bullosa wounded skin highlights drug repurposing opportunities to improve wound healing.
    Onoufriadis A; Proudfoot LE; Ainali C; Torre D; Papanikolaou M; Rayinda T; Rashidghamat E; Danarti R; Mellerio JE; Ma'ayan A; McGrath JA
    Exp Dermatol; 2022 Mar; 31(3):420-426. PubMed ID: 34694680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.